Get the Stockscreener App
6.74
0.07%
0.005
After Hours:
6.74
Diamedica Therapeutics Inc stock is traded at $6.74, with a volume of 89,709.
It is up +0.07% in the last 24 hours and up +2.90% over the past month.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
See More
Previous Close:
$6.735
Open:
$6.79
24h Volume:
89,709
Relative Volume:
0.46
Market Cap:
$363.17M
Revenue:
-
Net Income/Loss:
$-35.10M
P/E Ratio:
-9.5589
EPS:
-0.7051
Net Cash Flow:
$-31.49M
1W Performance:
-3.85%
1M Performance:
+2.90%
6M Performance:
-23.06%
1Y Performance:
+33.47%
1-Day Range:
$6.65
$7.1281
1-Week Range:
$6.54
$7.14
52-Week Range:
$4.0145
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Name
Diamedica Therapeutics Inc
Sector
Industry
Phone
(763) 496-5454
Address
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
6.74 | 362.90M | 0 | -35.10M | -31.49M | -0.7051 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-30-25 | Initiated | TD Cowen | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Jun-22-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-09-21 | Initiated | Oppenheimer | Outperform |
| Feb-17-21 | Initiated | ROTH Capital | Buy |
| Oct-30-20 | Initiated | Guggenheim | Buy |
| Jul-08-20 | Initiated | Maxim Group | Buy |
| Apr-30-19 | Initiated | Dougherty & Company | Buy |
| Mar-05-19 | Initiated | Lake Street | Buy |
View All
Diamedica Therapeutics Inc Stock (DMAC) Latest News
DiaMedica Therapeutics Inc. Revenue Breakdown – NASDAQ:DMAC - TradingView
DiaMedica Therapeutics Inc (DMAC) Income Statement - TradingKey
DiaMedica Therapeutics Inc (DMAC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
DiaMedica Therapeutics Inc (DMAC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
DiaMedica Therapeutics Market Sentiment - Benzinga España
DiaMedica Therapeutics Inc (DMAC) Cash Flow - TradingKey
DiaMedica Therapeutics Inc (DMAC) Balance Sheet - TradingKey
DiaMedica Therapeutics Inc (DMAC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
DMAC|DiaMedica Therapeutics Inc|Price:6.735|Chg%:-0.085 - TradingKey
DiaMedica Therapeutics Inc (DMAC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price to book forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
$7.37 | DiaMedica Therapeutics Inc. Common Stock (DMAC) Stock Price Today - Binance
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
(DMAC) Risk Channels and Responsive Allocation - Stock Traders Daily
DiaMedica Therapeutics (DMAC) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
DMAC Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Yield Spread - DonanımHaber
DMAC PE Ratio & Valuation, Is DMAC Overvalued - Intellectia AI
Enterprise value to EBITDA forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
DiaMedica Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Enterprise value to revenue forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
Price to sales forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
DMAC Q1 2026 Earnings: EPS Misses Estimates as Clinical Pipeline AdvancesEarnings Growth Forecast - dars.gov.et
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
DiaMedica Therapeutics Inc. Actuals & Estimates (NASDAQ:DMAC) - TradingView
DMAC Forecast — Price Target — Prediction for 2027 - TradingView
DiaMedica Therapeutics Up 10%, Insider Buyers Are Up 43% - simplywall.st
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - BioSpace
DiaMedica Therapeutics (DMAC) Initiates Phase 2 Trial for DM199 in Fetal Growth Restriction - GuruFocus
DiaMedica doses first patients in fetal growth restriction trial - Investing.com
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating - Moomoo
DiaMedica Therapeutics Inc (DMAC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
DiaMedica Therapeutics Inc (DMAC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
DiaMedica Therapeutics Inc (DMAC) Valuation: PE, PB & Fair Value Analysis - TradingKey
DiaMedica Therapeutics Inc (DMAC) Institutional Confidence - TradingKey
DiaMedica Therapeutics Inc - TradingKey
DiaMedica Therapeutics receives written response from FDA on DM199 - TipRanks
DiaMedica Therapeutics (DMAC) Updates on FDA Response for DM199 Development - GuruFocus
DiaMedica to conduct rat study addressing FDA data request - Investing.com
DiaMedica to conduct rat study addressing FDA data request By Investing.com - Investing.com Canada
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program - Business Wire
DiaMedica Therapeutics (DMAC) Hovers Near Key Support After Slight PullbackGrowth Stock Picks - newsline.com
DMAC Q1 2026 Earnings: Clinical Progress Drives Optimism Despite Slight EPS MissEarnings Miss Streak - newsline.com
DiaMedica Therapeutics (DMAC) Gains 3.66% as Biotech Stock Tests Key Resistance ZonePut Spread Alert - newsline.com
DiaMedica Therapeutics (DMAC) director granted 40,412 stock options at $5.84 - Stock Titan
DiaMedica (DMAC) director Richard Kuntz receives grant of 40,412 stock options - Stock Titan
DiaMedica Therapeutics (DMAC) director granted 40,412-share stock option award - Stock Titan
DiaMedica (DMAC) director Tanya Lewis awarded 40,412 stock options at $5.84 - Stock Titan
DiaMedica Therapeutics (DMAC) director receives 40,412-share stock option grant - Stock Titan
DiaMedica Therapeutics (NASDAQ: DMAC) director receives grant of 51,189 stock options - Stock Titan
DiaMedica Therapeutics (DMAC) CEO awarded 380,000 stock options - Stock Titan
DiaMedica Therapeutics (DMAC) CFO awarded 162,000 stock options at $5.84 strike - Stock Titan
Diamedica Therapeutics Inc Stock (DMAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):